Preclinical evaluation of the anti-tumor activity of pralatrexate in high-risk neuroblastoma cells.
CONCLUSIONS: Pralatrexate demonstrated effective inhibition of cell growth and viability. The higher potency of pralatrexate compared to methotrexate, a drug with high levels of toxicity, suggests pralatrexate may be a safer alternative to methotrexate as an effective chemotherapeutic agent in the treatment of patients with high-risk neuroblastoma.
PMID: 32850011 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
More News: Brain | Cancer & Oncology | Chemotherapy | Children | Methotrexate | Neuroblastoma | Neurology | Toxicology